Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice

European Journal of Pharmacology

Volumn 615, Issue 1-3, 2009, Pages 201-206

  Ito, Yoshihiko ^a   Oyunzul, Luvsandorj ^a   Yoshida, Akira ^a   Fujino, Tomomi ^a   Noguchi, Yukiko ^b   Yuyama, Hironori ^b   Ohtake, Akiyoshi ^b   Suzuki, Masanori ^b   Sasamata, Masao ^b   Matsui, Minoru ^c   Yamada, Shizuo ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

^c CHIBA INSTITUTE OF SCIENCE   (Japan)

Author keywords

Bladder; Muscarinic receptor binding; Muscarinic receptor KO mice; Solifenacin; Submandibular gland

Indexed keywords

METHYLSCOPOLAMINE; MUSCARINIC RECEPTOR; OXYBUTYNIN; RADIOLIGAND; SOLIFENACIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLADDER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LIGAND BINDING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBMANDIBULAR GLAND; WILD TYPE;

ADMINISTRATION, ORAL; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MANDELIC ACIDS; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, KNOCKOUT; MUSCARINIC ANTAGONISTS; PROTEIN BINDING; QUINUCLIDINES; RADIOLIGAND ASSAY; RECEPTOR, MUSCARINIC M2; RECEPTOR, MUSCARINIC M3; SUBMANDIBULAR GLAND; TETRAHYDROISOQUINOLINES; URINARY BLADDER;

EID: 67649105375     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.04.068     Document Type: Article

References (47)

1. Abrams P., Freeman R., Anderstrom C., and Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br. J. Pharmacol. 81 (1998) 801-810
2. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., Van Kerrebroeck P., Victor A., and Wein A. Standardization Sub-committee of the International Continence Society. The standardization of terminology of lower urinary tract function: report from the Standardization Sub-committee of the International Committee Society. Neurourol. Urodyn. 21 (2002) 167-178
3. Andersson K.E. Antimuscarinics for the treatment of overactive bladder. Lancet Neurol. 3 (2004) 46-53
4. Andersson K.E., Holmquist F., Fovaeus M., Hedlund H., and Sundler R. Muscarinic receptor stimulation of phosphoinositide hydrolysis in the human isolated urinary bladder. J. Urol. 146 (1991) 1156-1159
5. Beauchamp H.T., Chang R.S.L., Sigel P.K.S., and Gibson R.E. In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency. J. Pharmacol. Exp. Ther. 272 (1995) 612-618
6. 5 muscarinic receptor knockout mice as novel tools to lineate the physiological roles of the muscarinic cholinergic system. Neurochem. Res. 28 (2003) 437-442
7. Caulfield M.P. Muscarinic receptor: characterization, coupling and function. Pharmacol. Ther. 58 (1993) 319-379
8. Chapple C.R. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55 (2000) 33-46
9. 3 muscarinic receptors in rat parotid gland couple to two second messenger systems. Am. J. Physiol. 261 (1991) C1063-C1073
10. Durlu-Kandilci N.T., and Brading A.F. Involvement of Rho kinase and protein kinase C in carbachol-induced calcium sensitization in β-escin skinned rat and guinea-pig bladders. Br. J. Pharmacol. 148 (2006) 376-384
11. Eglen R.M., and Watson N. Selective muscarinic receptor agonists and antagonists. Pharmacol. Toxicol. 78 (1996) 59-68
12. Eglen R.M., Reddy H., Watson N., and Challis R.A.J. Muscarinic acetylcholine receptors in smooth muscle. Trends Pharmacol. Sci. 15 (1994) 114-119
13. 2 subtypes of muscarinic binding sites in rat brain. J. Pharmacol. Exp. Ther. 255 (1990) 1148-1157
14. 3 muscarinic receptor single- and double-knockout mice. Mol. Pharmacol. 66 (2004) 260-267
15. 3-receptors coupled to inositol phospholipid hydrolysis in human detrusor cultured smooth muscle cells. J. Urol. 154 (1995) 1241-1245
16. Hulme E.C., Birdsall N.J.M., and Buckley N.J. Muscarinic receptor subtypes. Annu. Rev. Pharmacol. Toxicol. 30 (1990) 633-673
17. 3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch. Pharmacol. 366 (2002) 97-103
18. 5 single knockout mice. Br. J. Pharmacol. 156 (2009) 1147-1153
19. Jezior J.R., Brady J.D., Rosenstein D.I., McCammon K.A., Miner A.S., and Ratz P.H. Dependency of detrusor contractions on calcium sensitization and calcium entry through LOE-908-sensitive channels. Br. J. Pharmacol. 134 (2001) 78-87
20. Karasawa H., Taketo M.M., and Matsui M. Loss of anti-cataleptic effect of scopolamine in mice lacking muscarinic acetylcholine receptor subtype 4. Eur. J. Pharmacol. 468 (2003) 15-19
21. Kenakin T. Predicting therapeutic value in the lead optimization phase of drug discovery. Nat. Rev. Drug Discov. 2 (2003) 429-438
22. 2+ mobilization study in monkey cells. Life Sci. 74 (2004) 843-853
23. 3 receptors are coupled to two signal transduction pathways in rat submandibular cells. Eur. J. Pharmacol. 188 (1990) 171-174
24. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
25. 3 subtype. Proc. Natl. Acad. Sci. USA 97 (2000) 9579-9584
26. 3 muscarinic acetylcholine receptors are devoid of cholinergic smooth muscle contractions but still viable. J. Neurosci. 22 (2002) 10627-10632
27. Matsui M., Yamada S., Oki T., Manabe T., Taketo M., and Ehlert F.J. Functional analysis of muscarinic acetylcholine receptors using knockout mice. Life Sci. 75 (2004) 2971-2981
28. 3 muscarinic acetylcholine receptor plays a critical role in parasympathetic control of salivation in mice. J. Physiol. 558 (2004) 561-575
29. Nilvebrant L., Andersson K.E., Gillberg P.G., Stahl M., and Sparf B. Tolterodine-a new bladder-selective antimuscarinic agent. Eur. J. Pharmacol. 327 (1997) 195-207
30. 1-adrenoceptors in rat tissues in relation to the plasma concentration. Life Sci. 63 (1998) 2147-2155
31. Ohtake A., Ukai M., Hatanaka T., Kobayashi S., Ikeda K., Sato S., Miyata K., and Sasamata M. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur. J. Pharmacol. 492 (2004) 243-250
32. Ohtake A., Saitoh C., Yuyama H., Ukai M., Okutsu H., Noguchi Y., Hatanaka T., Suzuki M., Sato S., Sasamata M., and Miyata K. Pharmacologial characterization of a new antimuscarinic agent, solifenacin succcinate, in comparison with other antimuscarinic agents. Biol. Pharm. Bull. 30 (2006) 54-58
33. Oki T., Kimura R., Saito M., Miyagawa I., and Yamada S. Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J. Urol. 172 (2004) 2059-2064
34. Oki T., Sato S., Miyata K., and Yamada S. Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice. Br. J. Pharmacol. 145 (2005) 219-227
35. Oki T., Takeuchi C., and Yamada S. Comparative evaluation of exocrine muscarinc receptor binding characteristics and inhibition of salivation of solifenacin in mice. Biol. Pharm. Bull. 29 (2006) 1397-1400
36. Okutsu H., Noguchi Y., Ohtake A., Suzuki M., Sato S., and Sasamata M. Effects of intravenously and orally administered solifenacin succinate (YM905) on carbachol-induced intravesical pressure elevation and salivary secretion in mice. Biol. Pharm. Bull. 30 (2007) 2324-2327
37. Schneider T., Fetscher C., Krege S., and Michel M.C. Signal transduction underlying carbachol-induced contraction of human urinary bladder. J. Pharmacol. Exp. Ther. 309 (2004) 1148-1153
38. Staskin D.R., and MacDiarmid S.A. Using anticholinergic agents to treat overactive bladder: the issue of treatment tolerability. Am. J. Med. 119 (2006) 9S-15S
39. Uchida S., Yamada S., Ohkura T., Heshikiri M., Yoshimi A., Shirahase H., and Kimura R. The receptor occupation and plasma concentration of NKY-722, a water-soluble dihydropyridine-type calcium antagonist, in spontaneously hypertensive rats. Br. J. Pharmacol. 114 (1995) 217-223
40. 5 muscarinic receptor knockout mice as novel tools to study the physiological roles of the muscarinic cholinergic system. Recept. Channels. 9 (2003) 279-290
41. Wess J., Eglen R.M., and Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat. Rev. Drug Discov. 6 (2007) 721-733
42. Wibberley A., Chen Z., Hu E., Hieble J.P., and Westfall T.D. Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle. Br. J. Pharmacol. 138 (2003) 757-766
43. 3H]WB4101: effect of 6-hydroxydomine treatment. J. Pharmacol. Exp. Ther. 215 (1980) 176-185
44. 1A-adrenoceptor subtype selectivity of KMD-3213 in rat tissues. J. Pharmacol. Exp. Ther. 296 (2001) 160-167
45. Yamada S., Nakajima M., Kusaka T., Uchida S., and Kimura R. In vivo receptor binding of benidipine and amlodipine in mesenteric arteries and other tissues of spontaneously hypertensive rats. Life Sci. 70 (2002) 1999-2011
46. 35S]GTPgS in rat brain and spinal cord. Br. J. Pharmacol. 139 (2003) 1462-1468
47. Yarker Y.E., Goa K.L., and Fitton A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 6 (1995) 243-262